Research
Print page Print page
Switch language
The Capital Region of Denmark - a part of Copenhagen University Hospital
Published

The current epidemic of HPV-associated oropharyngeal cancer: An 18-year Danish population-based study with 2,169 patients

Research output: Contribution to journalJournal articleResearchpeer-review

  1. Initial treatment and survival in 4163 Danish patients with pancreatic cancer: A nationwide unselected real-world register study

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. Measured and genetically predicted plasma YKL-40 levels and melanoma mortality

    Research output: Contribution to journalJournal articleResearchpeer-review

  3. Phase II randomised discontinuation trial of brivanib in patients with advanced solid tumours

    Research output: Contribution to journalJournal articleResearchpeer-review

  1. Association between head and neck cancer and sexually transmitted diseases: a Danish nationwide, case-control study

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. Circulating tumour DNA alterations as biomarkers for head and neck cancer: a systematic review

    Research output: Contribution to journalReviewResearchpeer-review

  3. Trends of ankyloglossia and lingual frenotomy in hospital settings among children in Denmark

    Research output: Contribution to journalJournal articleResearchpeer-review

  4. High nodal FDG uptake increases risk of distant metastasis in patients with oropharyngeal squamous cell carcinoma

    Research output: Contribution to journalJournal articleResearchpeer-review

View graph of relations

BACKGROUND: The objectives of this study were to investigate the incidence of high-risk genotypes of human papillomavirus (HPV) in tumours of patients with oropharyngeal squamous cell carcinoma (OPSCC) during an 18-year period in Eastern Denmark.

METHODS: In this population-based, consecutive, semi-national registry study, all patients diagnosed with OPSCC from 2000 to 2017 in Eastern Denmark were evaluated at head and neck oncological departments at public university hospitals. Analyses included tumour characteristics (HPV-positive [HPV+] versus HPV-negative [HPV-]), age-adjusted incidence rates (AAIRs), average annual percentage change (AAPC) of OPSCC, and patient demographics. All HPV+ cases from 2011 to 2017 were genotyped.

RESULTS: In total, 55% of 2169 OPSCC cases were HPV+. HPV16, HPV33, HPV35 or other types were found in 86%, 7.4%, 3.4% and 3.2% of cases, respectively. The AAIR per 100,000 of all OPSCCs was 1.8 in 2000, which increased to 5.1 in 2017 (HPV+: threefold increase, HPV-: twofold increase). The AAPC from 2000 to 2017 increased by 7% (HPV+ increased by 10% and HPV- by 4%). The median age at diagnosis for all OPSCC cases increased during the 18-year study period (HPV+: 58-61 years, p < 0.001; HPV-: 60-65 years, p < 0.001).

CONCLUSION: We report a threefold increase in OPSCC incidence during the 18-year observation period and a significant increase in median age at diagnosis. Over 93% of HPV genotypes in HPV+ OPSCC are included in current HPV vaccines except for HPV35 (4%). HPV vaccination of both sexes is advised to halt this emerging cancer epidemic.

Original languageEnglish
JournalEuropean journal of cancer (Oxford, England : 1990)
Volume134
Pages (from-to)52-59
Number of pages8
ISSN0959-8049
DOIs
Publication statusPublished - Jul 2020

ID: 60285634